Avagacestat (Standard)
Avagacestat (Standard) is the analytical standard of Avagacestat. This product is intended for research and analytical applications. Avagacestat (BMS-708163) is a potent inhibitor of γ-secretase, with IC50s of 0.27 nM and 0.30 nM for Aβ42 and Aβ40 inhibition; Avagacestat (BMS-708163) also inhibits NICD (Notch IntraCellular Domain) with IC50 of 0.84 nM and shows weak inhibition of CYP2C19, with IC50 of 20 μM. Avagacestat can be used for Alzheimer disease research.
Product Specifications
CAS Number
1146699-66-2
UNSPSC
12352100
Target
Notch; Reference Standards; γ-secretase
Related Pathways
Neuronal Signaling; Others; Stem Cell/Wnt
Field of Research
Cancer
Smiles
O=S(N([C@@H](C(N)=O)CCC(F)(F)F)CC1=CC=C(C2=NOC=N2)C=C1F)(C3=CC=C(Cl)C=C3)=O
Molecular Formula
C20H17ClF4N4O4S
Molecular Weight
520.89
References & Citations
[1]Gillman KW, et al. Letter Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor. Med Chem Lett, 2010, 1 (3), 120-124.|[2]Crump CJ, et al. BMS-708,163 targets presenilin and lacks notch-sparing activity. Biochemistry. 2012 Sep 18;51 (37) :7209-11.|[3]Xie M, et al. γ Secretase inhibitor BMS-708163 reverses resistance to EGFR inhibitor via the PI3K/Akt pathway in lung cancer. J Cell Biochem. 2015 Jun;116 (6) :1019-27.|[4]Borghys H, et al. A canine model to evaluate efficacy and safety of γ-secretase inhibitors and modulators. J Alzheimers Dis. 2012;28 (4) :809-22.|[5]Vladimir Coric, et al. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol. 2012 Nov;69 (11) :1430-40.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
PKSH031307 100 µg
Recombinant Human CCNA1/Cyclin-A1 Protein (His Tag)
Sign In for Pricing
View Details 
